The American Society of Hematology (ASH) released one month ahead the abstracts and we are excited not having to wait until December during the San Diego – CA meeting. What we see on as highlights on the CART front:
- Bluebird bio inc reported data from the Phase I trial to treat relapsed or refractory MM showing that its bb21217 led to a response rate of 85% per International Myeloma Working Group (IMWG) criteria. bb21217 is the company’s next-generation lentiviral CAR T therapy targeting BCMA.
- Juno Therapeutics Inc. subsidiary of Celgene Corp. reported the first data for its JCARH125, in the Phase I/II trial to treat relapsed and/or refractory MM patients. Juno said JCARH125 led to evidence of an objective response in all evaluable patients.
- GenScript Biotech Corp. unit Nanjing Legend Biotech Co. Ltd. reported updated data from the Phase I portion of the Chinese Phase I/II trial showing that its CAR T cell therapy LCAR-B38M, led to an overall response rate (ORR) of 88% among 57 relapsed or refractory MM patients. Johnson & Johnson holds global rights to jointly develop and commercialize LCAR-B38M under the compound name JNJ-68284528 with GenScript subsidiaries Legend Biotech USA Inc. and Legend Biotech Ireland Ltd. to treat MM.